IP Library Granted Patent US 10,815,195
Granted Patent B2
US 10,815,195 · App. 15/694,303 · Granted Oct 27, 2020

Oxygenated amino- or ammonium-containing sulfonic acid, phosphonic acid and carboxylic acid derivatives and their medical use

Inventors: Georg Schlechtingen (Dresden, DE); Hans-Joachim Knolker (Dresden, DE); Tim Friedrichson (Dresden, DE); Gary Jennings (Dresden, DE); Tobias Braxmeier (Kuppenheim, DE)
Assignee: GRI Bio, Inc.
C07C309/14A61K31/205
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,815,195
App. No.
15/694,303
Granted
Oct 27, 2020
Kind
B2
Abstract

The present invention relates to oxygenated amino or ammonium-containing sulfonic acid, phosphoric acid and carboxylic acid derivatives, in particular the compounds of formula 1, 2, 3, 4, 5 or 6, and their medical use, including their use in the treatment, prevention or amelioration of an inflammatory, autoimmune and/or allergic disorder, or a proliferative, neoplastic or dysplastic disease or disorder.

Claims (22)

1. A compound of the following formula 1

wherein

R 1 is a C 10-20 hydrocarbon group;

R 2 is a C 1-4 alkyl group, and R 3 is —H, or R 3 is absent;

R 4 is a C 3-6 alkylene group which is substituted with one or more groups independently selected from OH, —O(C 1-3 alkyl), —O—C(O)—(C 1-3 alkyl), —O—C(O)—O(C 1-3 alkyl), —O—C(O)—NH 2 , —O—C(O)—NH(C 1-3 alkyl), —O—C(O)—N(C 1-3 alkyl)(C 1-3 alkyl), —O(CH 2 ) 2 OH, or —O(CH 2 ) 3 OH;

R 5 is —PO 3 2− , —PO 3 H − , or —PO 3 H 2 ; and

X is N + or, if R 3 is absent, X is N;

or a pharmaceutically acceptable salt, or solvate thereof.

2. A compound of the following formula 1b:

or a pharmaceutically acceptable salt, or solvate thereof.

3. A compound of the following formula 1

wherein

R 1 is a C 10-20 hydrocarbon group;

R 2 is a C 1-4 alkyl group, and R 3 is —H, or R 3 is absent;

R 4 is a C 3-6 alkylene group which is substituted with one or more groups independently selected from —OH, —O(C 1-3 alkyl), —O—C(O)—(C 1-3 alkyl), —O—C(O)—C(C 1-3 alkyl), —O—C(O)—NH 2 , —O—C(O)—NH(C 1-3 alkyl), —O—C(O)—N(C 1-3 alkyl)(C 1-3 alkyl), —O(CH 2 ) 2 OH, or —O(CH 2 ) 3 OH;

R 5 is —SO 3 − , —SO 3 H, —PO 3 H − , —PO 3 2− , —PO 3 H 2 , —PO 2 (OC 1-3 alkyl) − , —PO 2 H(OC 1-3 alkyl), —PO(OC 1-3 alkyl) 2 , —CO 2 —, —CO 2 H, or —CO 2 (C 1-3 alkyl); and

X is N + or, if R 3 is absent, X is N;

or a pharmaceutically acceptable salt, or solvate thereof, wherein the compound does not comprise formula 1a:

4. A compound of the following formula 1c:

or a pharmaceutically acceptable salt, or solvate thereof.

5. A compound of the following formula 1d or 1e:

or a pharmaceutically acceptable salt or solvate thereof.

Assignments (4)
SECURITY INTEREST Recorded Dec 15, 2022
From: GRI BIO, INC.
To: ALTIUM GROWTH FUND, LP
Reel/Frame 062108/0599 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2020
From: SCHLECHTINGEN, GEORG; KNOLKER, HANS-JOACHIM; FRIEDRICHSON, TIM; JENNINGS, GARY; BRAXMEIER, TOBIAS
To: GLYCOREGIMMUNE, INC.
Reel/Frame 053809/0122 →
CHANGE OF NAME Recorded Sep 17, 2020
From: GLYCOREGIMMUNE, INC.
To: GRI BIO, INC.
Reel/Frame 053812/0135 →
SECURITY INTEREST Recorded Nov 2, 2018
From: GRI BIO, INC.
To: TEP BIOTECH, LLC
Reel/Frame 047399/0239 →
Priority Claims (1)
EP 11167731 · May 26, 2011 · regional
Continuity (2)
Continuation 14403168
Related Publication 20170369430A1 · Dec 28, 2017
Cited By (1)
US 12,528,775